首页> 外国专利> FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PREPARING OPHTHALMIC DISEASE TREATMENT,ANTI-INFLAMMATION AND ANTI-TUMOR MEDICAMENT

FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PREPARING OPHTHALMIC DISEASE TREATMENT,ANTI-INFLAMMATION AND ANTI-TUMOR MEDICAMENT

机译:融合蛋白,其制备方法及其应用在制备眼科疾病治疗,抗炎和抗肿瘤药物中的应用

摘要

The invention discloses a fusion protein, a preparation method thereof and application thereof in preparing ophthalmic disease treatment, anti-inflammation and anti-tumor medicament, and belongs to the field of biopharmaceutical technology. The present invention uses a flexible (F) or rigid (R) linker to fuse two polypeptides to respectively obtain two bifunctional fusion proteins, namely two multi-functional fusion protein macromolecules obtained by linking antiangiogenesis polypeptides HM-3, IL-4 and immunoglobulin Fc fragments via an amino acid linker, which can improve drug efficacy, prolong half-life and enhance stability, has the characteristics of strong effect, low toxicity and the like, and can be used for the prevention and treatment of solid tumors and various types of inflammations and neovascular ophthalmic diseases. The fusion protein is expressed in a eukaryotic cell by a genetic engineering method and purified by affinity chromatography or the like.
机译:本发明公开了一种融合蛋白,其制备方法及其应用在制备眼科疾病治疗,抗炎和抗肿瘤药物中,属于生物制药技术领域。本发明使用柔性(F)或刚性(R)接头来熔化两种多肽,分别获得两种双官能融合蛋白,即通过连接抗脑生成多肽HM-3,IL-4和免疫球蛋白FC而获得的两个多功能融合蛋白大分子通过氨基酸接头的片段,可以改善药物功效,延长半衰期并增强稳定性,具有强效应,低毒性等的特点,可用于预防和治疗实体瘤和各种类型炎症和新生血管眼科疾病。融合蛋白通过基因工程方法在真核细胞中在真核细胞中表达,并通过亲和层析等纯化。

著录项

  • 公开/公告号US2021107960A1

    专利类型

  • 公开/公告日2021-04-15

    原文格式PDF

  • 申请/专利权人 JIANGSU RONGTAI BIOTECH CO. LTD.;

    申请/专利号US201816496397

  • 发明设计人 HANMEI XU;

    申请日2018-03-05

  • 分类号C07K14/54;C07K14/475;A61K38;A61P27/02;A61P19/02;A61P29;

  • 国家 US

  • 入库时间 2022-08-24 18:14:29

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号